MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.biocel.2025.106786

Медицинская библиотека · The international journal of biochemistry & cell biology · 2025

Acalabrutinib alleviates metabolic dysfunction-associated steatotic liver disease by regulating bile acid metabolism.

Wang Yanbo, Chen Shiwei, Ye Bingjue, Yang Zhenggang, Liu Yanning, Lou Guohua, Zhou Cheng, Zheng Min

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global epidemic of chronic liver disease currently lacking effective treatment. Evaluating the therapeutic effects of existing drugs on MASLD is a time and cost-effective strategy. Bruton's tyrosine kinase (BTK) is an inflammatory signaling molecule playing an important role in the progression of MASLD. Aclabrutinib, a BTK inhibitor approved for treating mantle-cell lymphoma and chronic lymphocytic leukemia, has not been investigated for its potential to treat MASLD. This study examined the therapeutic effects and mechanisms of aclabrutinib on MASLD using a high-fat diet-induced mouse model. Results demonstrated significant alleviation of pathological parameters associated with MASLD upon administration of aclabrutinib. TSE PhenoMaster results revealed that aclabrutinib increased energy expenditure in mice. Furthermore, aclabrutinib upregulated the expression of genes associated with thermogenesis and lipolysis in adipose tissues. Additionally, it inhibited the transcription of genes related to lipid absorption in the small intestine and liver, while increasing the expression of hormone-sensitive lipase, hepatic nuclear factor 4 alpha and fibroblast growth factor 21 in the liver. Further analysis indicated that aclabrutinib promoted the alternative pathway of bile acid synthesis while restoring gut microbiota homeostasis. The altered bile acid profiles upregulated G protein-coupled bile acid receptor 1 expression in adipose tissues as well as vitamin D receptor expression in liver and small intestine. Our findings suggest that by regulating bile acid metabolism and gut microbiota, aclabrutinib may promote thermogenesis and lipolysis, thereby alleviating MASLD. This study provides novel insights into clinical applications targeting BTK for treating MASLD.

Для цитирования: Wang Yanbo, Chen Shiwei, Ye Bingjue, Yang Zhenggang, Liu Yanning, Lou Guohua, Zhou Cheng, Zheng Min. Acalabrutinib alleviates metabolic dysfunction-associated steatotic liver disease by regulating bile acid metabolism.. The international journal of biochemistry & cell biology. 2025. DOI: 10.1016/j.biocel.2025.106786.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.